Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reslizumab - Teva Pharmaceuticals

Next Previous
Drug Profile

Reslizumab - Teva Pharmaceuticals

Alternative Names: Anti-interleukin-5-monoclonal antibody-Celltech/Schering-Plough; CDP-835; CEP-38072; CINQAERO; CINQAIR; Cinquil; CTx-55700; DCP-835; SCH 55700; TRFK-5

Latest Information Update: 06 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celltech R&D; Schering-Plough
  • Developer Allergy and Asthma Clinical Research; Celltech R&D; Teva Pharmaceutical Industries
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Phase III Sinusitis
  • Phase II Churg-Strauss syndrome
  • No development reported Oesophagitis

Most Recent Events

  • 06 Feb 2023 Launched for Asthma in Austria, Greece, Belgium, Finland, Spain, Denmark, Sweden, Portugal, Czech Republic, Netherlands, Poland, Hungary, United Kingdom, Russia, Norway (IV) prior to February 2023
  • 19 Feb 2021 Discontinued - Phase-III for Asthma (In adolescents, In the elderly, Treatment-experienced, In adults) in New Zealand, Poland, Belgium, Russia, Australia, Hungary, South Africa, Spain, Ukraine, Argentina, France, Germany, Czech Republic, Israel, Italy, Mexico, South Korea, Canada, Netherlands, Japan, Turkey, Romania, USA (SC) (Teva Pharmaceuticals pipeline, February 2021)
  • 10 Feb 2021 National Jewish Health completes a phase II trial in Churg-Strauss syndrome in USA (IV) (NCT02947945)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top